EBIDTA improved by 47.5% to Rs 80.5 crore in Q4 FY22 from Rs 54.6 crore in Q4 FY21. EBIDTA margin was 20.1% in the fourth quarter as against 18.5% in the same period last year.

Operating profit jumped by 65.1% YoY to Rs 79.1 crore during the quarter.

The company recorded 67.2% increase in standalone net profit to Rs 154.5 crore on a 23.4% rise in net revenues to Rs 1,502.7 crore in FY22 over FY21.

Aditi Panandikar, managing director, Indoco Remedies, said, “An excellent sales growth has resulted in an impressive financial performance inspite of various challenges, primarily higher input and freight costs.”

Indoco Remedies is a fully integrated, research-oriented pharma company with presence in 55 countries.